Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis

Ying Ying Leung; W Tillett; Pil Hojgaard; Ana-Maria Orbai; Richard Holland; Ashish J Mathew; Niti Goel; Jeffrey Chau; Chris Lindsay; Alexis Ogdie; Laura C. Coates; Robin Christensen; Philip Mease; Vibeke Strand; Dafna D Gladman

doi:10.3899/jrheum.210175

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis

Ying Ying Leung, W Tillett, Pil Hojgaard, Ana-Maria Orbai, Richard Holland, Ashish J Mathew, Niti Goel, Jeffrey Chau, Chris Lindsay, Alexis Ogdie, Laura C. Coates, Robin Christensen, Philip Mease, Vibeke Strand, Dafna D Gladman

Research output: Contribution to journal › Article › peer-review

7 Citations (SciVal)

Abstract

Objective. Due to no existing data, we aimed to derive evidence to support test-retest reliability for the Health Assessment Questionnaire–Disability Index (HAQ-DI) and 36-item Short Form Health Survey physical functioning domain (SF-36 PF) in psoriatic arthritis (PsA). Methods. We identified datasets that collected relevant data for test-retest reliability for HAQ-DI and SF-36 PF, and evaluated them using Outcome Measures in Rheumatology (OMERACT) Filter 2.1 methodology. We calculated intraclass correlation coefficients (ICC) as a measure of test-retest reliability. We then conducted a quality assessment and evaluated the adequacy of test-retest reliability performance. Results. Two datasets were identified for HAQ-DI and 1 for SF-36 PF in PsA. The quality of the datasets was good. The ICCs for HAQ-DI were good and excellent in study 1 (0.90, 95% CI 0.79–0.95) and study 2 (0.94, 95% CI 0.89–0.97). The ICC for SF-36 PF was excellent (0.96, 95% CI 0.92–0.98). The performance of test-retest reliability for both instruments was judged to be adequate. Conclusion. The new data derived support good and reasonable test-retest reliability for HAQ-DI and SF-36 PF in PsA.

Original language	English
Pages (from-to)	1547-1551
Number of pages	5
Journal	The Journal of Rheumatology
Volume	48
Issue number	10
Early online date	15 Apr 2021
DOIs	https://doi.org/10.3899/jrheum.210175
Publication status	Published - 1 Oct 2021

Bibliographical note

Funding Information:
YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) are supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a National Institute for Health Research (NIHR) Clinician Scientist award, and the NIHR Oxford Biomedical Research Centre (BRC). AO is funded by NIH/ National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR072363). WT is supported by the NIHR, Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the funding agencies. 1Y.Y. Leung, MB ChB, MD, Singapore General Hospital, and Duke-NUS Medical School, Singapore; 2W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; 3P. Hojgaard, MD, PhD, Department of Rheumatology, Holbæk Hospital, Holbæk, and Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 4A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 5R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; 6A.J. Mathew, MBBS, DNB, DM, The Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Disorders, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark, and Centre for Prognosis Studies in Rheumatic Diseases, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada, and Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India; 7N. Goel, MD, Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; 8J. Chau, BA, MCS, Patient Research Partner, Hong Kong; 9C.A. Lindsay, PharmD, Patient Research Partner, employed by Aurinia Pharma US Inc., Prosper, Texas, USA; 10A. Ogdie, MD, MSCE, Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 11L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 12R. Christensen, BSc, MSc, PhD, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; 13P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; 14V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; 15D.D. Gladman, MD, FRCPC, Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, level 4, 20 College Road, Singapore 169856, Singapore. Email: [email protected]. Accepted for publication April 6, 2021.

Publisher Copyright:
© 2021 The Journal of Rheumatology.

Keywords

Patient-reported outcome
Physical function
Psoriatic arthritis
Test-retest reliability

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology

Access to Document

10.3899/jrheum.210175

Cite this

Leung, Y. Y., Tillett, W., Hojgaard, P., Orbai, A.-M., Holland, R., Mathew, A. J., Goel, N., Chau, J., Lindsay, C., Ogdie, A., Coates, L. C., Christensen, R., Mease, P., Strand, V., & Gladman, D. D. (2021). Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis. The Journal of Rheumatology, 48(10), 1547-1551. https://doi.org/10.3899/jrheum.210175

Leung, YY, Tillett, W, Hojgaard, P, Orbai, A-M, Holland, R, Mathew, AJ, Goel, N, Chau, J, Lindsay, C, Ogdie, A, Coates, LC, Christensen, R, Mease, P, Strand, V & Gladman, DD 2021, 'Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis', The Journal of Rheumatology, vol. 48, no. 10, pp. 1547-1551. https://doi.org/10.3899/jrheum.210175

@article{4e722a12f9e84b1f8de95fe9b8f6aa42,

title = "Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis",

abstract = "Objective. Due to no existing data, we aimed to derive evidence to support test-retest reliability for the Health Assessment Questionnaire–Disability Index (HAQ-DI) and 36-item Short Form Health Survey physical functioning domain (SF-36 PF) in psoriatic arthritis (PsA). Methods. We identified datasets that collected relevant data for test-retest reliability for HAQ-DI and SF-36 PF, and evaluated them using Outcome Measures in Rheumatology (OMERACT) Filter 2.1 methodology. We calculated intraclass correlation coefficients (ICC) as a measure of test-retest reliability. We then conducted a quality assessment and evaluated the adequacy of test-retest reliability performance. Results. Two datasets were identified for HAQ-DI and 1 for SF-36 PF in PsA. The quality of the datasets was good. The ICCs for HAQ-DI were good and excellent in study 1 (0.90, 95% CI 0.79–0.95) and study 2 (0.94, 95% CI 0.89–0.97). The ICC for SF-36 PF was excellent (0.96, 95% CI 0.92–0.98). The performance of test-retest reliability for both instruments was judged to be adequate. Conclusion. The new data derived support good and reasonable test-retest reliability for HAQ-DI and SF-36 PF in PsA.",

keywords = "Patient-reported outcome, Physical function, Psoriatic arthritis, Test-retest reliability",

author = "Leung, {Ying Ying} and W Tillett and Pil Hojgaard and Ana-Maria Orbai and Richard Holland and Mathew, {Ashish J} and Niti Goel and Jeffrey Chau and Chris Lindsay and Alexis Ogdie and Coates, {Laura C.} and Robin Christensen and Philip Mease and Vibeke Strand and Gladman, {Dafna D}",

note = "Funding Information: YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) are supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a National Institute for Health Research (NIHR) Clinician Scientist award, and the NIHR Oxford Biomedical Research Centre (BRC). AO is funded by NIH/ National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR072363). WT is supported by the NIHR, Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the funding agencies. 1Y.Y. Leung, MB ChB, MD, Singapore General Hospital, and Duke-NUS Medical School, Singapore; 2W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; 3P. Hojgaard, MD, PhD, Department of Rheumatology, Holb{\ae}k Hospital, Holb{\ae}k, and Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 4A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 5R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; 6A.J. Mathew, MBBS, DNB, DM, The Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Disorders, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark, and Centre for Prognosis Studies in Rheumatic Diseases, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada, and Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India; 7N. Goel, MD, Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; 8J. Chau, BA, MCS, Patient Research Partner, Hong Kong; 9C.A. Lindsay, PharmD, Patient Research Partner, employed by Aurinia Pharma US Inc., Prosper, Texas, USA; 10A. Ogdie, MD, MSCE, Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 11L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 12R. Christensen, BSc, MSc, PhD, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; 13P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; 14V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; 15D.D. Gladman, MD, FRCPC, Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, level 4, 20 College Road, Singapore 169856, Singapore. Email: [email protected]. Accepted for publication April 6, 2021. Publisher Copyright: {\textcopyright} 2021 The Journal of Rheumatology.",

year = "2021",

month = oct,

day = "1",

doi = "10.3899/jrheum.210175",

language = "English",

volume = "48",

pages = "1547--1551",

journal = "The Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "10",

}

TY - JOUR

T1 - Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis

AU - Leung, Ying Ying

AU - Tillett, W

AU - Hojgaard, Pil

AU - Orbai, Ana-Maria

AU - Holland, Richard

AU - Mathew, Ashish J

AU - Goel, Niti

AU - Chau, Jeffrey

AU - Lindsay, Chris

AU - Ogdie, Alexis

AU - Coates, Laura C.

AU - Christensen, Robin

AU - Mease, Philip

AU - Strand, Vibeke

AU - Gladman, Dafna D

N1 - Funding Information: YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) are supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a National Institute for Health Research (NIHR) Clinician Scientist award, and the NIHR Oxford Biomedical Research Centre (BRC). AO is funded by NIH/ National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR072363). WT is supported by the NIHR, Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the funding agencies. 1Y.Y. Leung, MB ChB, MD, Singapore General Hospital, and Duke-NUS Medical School, Singapore; 2W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; 3P. Hojgaard, MD, PhD, Department of Rheumatology, Holbæk Hospital, Holbæk, and Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 4A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 5R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; 6A.J. Mathew, MBBS, DNB, DM, The Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Disorders, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark, and Centre for Prognosis Studies in Rheumatic Diseases, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada, and Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India; 7N. Goel, MD, Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; 8J. Chau, BA, MCS, Patient Research Partner, Hong Kong; 9C.A. Lindsay, PharmD, Patient Research Partner, employed by Aurinia Pharma US Inc., Prosper, Texas, USA; 10A. Ogdie, MD, MSCE, Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 11L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 12R. Christensen, BSc, MSc, PhD, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; 13P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; 14V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; 15D.D. Gladman, MD, FRCPC, Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, level 4, 20 College Road, Singapore 169856, Singapore. Email: [email protected]. Accepted for publication April 6, 2021. Publisher Copyright: © 2021 The Journal of Rheumatology.

PY - 2021/10/1

Y1 - 2021/10/1

N2 - Objective. Due to no existing data, we aimed to derive evidence to support test-retest reliability for the Health Assessment Questionnaire–Disability Index (HAQ-DI) and 36-item Short Form Health Survey physical functioning domain (SF-36 PF) in psoriatic arthritis (PsA). Methods. We identified datasets that collected relevant data for test-retest reliability for HAQ-DI and SF-36 PF, and evaluated them using Outcome Measures in Rheumatology (OMERACT) Filter 2.1 methodology. We calculated intraclass correlation coefficients (ICC) as a measure of test-retest reliability. We then conducted a quality assessment and evaluated the adequacy of test-retest reliability performance. Results. Two datasets were identified for HAQ-DI and 1 for SF-36 PF in PsA. The quality of the datasets was good. The ICCs for HAQ-DI were good and excellent in study 1 (0.90, 95% CI 0.79–0.95) and study 2 (0.94, 95% CI 0.89–0.97). The ICC for SF-36 PF was excellent (0.96, 95% CI 0.92–0.98). The performance of test-retest reliability for both instruments was judged to be adequate. Conclusion. The new data derived support good and reasonable test-retest reliability for HAQ-DI and SF-36 PF in PsA.

AB - Objective. Due to no existing data, we aimed to derive evidence to support test-retest reliability for the Health Assessment Questionnaire–Disability Index (HAQ-DI) and 36-item Short Form Health Survey physical functioning domain (SF-36 PF) in psoriatic arthritis (PsA). Methods. We identified datasets that collected relevant data for test-retest reliability for HAQ-DI and SF-36 PF, and evaluated them using Outcome Measures in Rheumatology (OMERACT) Filter 2.1 methodology. We calculated intraclass correlation coefficients (ICC) as a measure of test-retest reliability. We then conducted a quality assessment and evaluated the adequacy of test-retest reliability performance. Results. Two datasets were identified for HAQ-DI and 1 for SF-36 PF in PsA. The quality of the datasets was good. The ICCs for HAQ-DI were good and excellent in study 1 (0.90, 95% CI 0.79–0.95) and study 2 (0.94, 95% CI 0.89–0.97). The ICC for SF-36 PF was excellent (0.96, 95% CI 0.92–0.98). The performance of test-retest reliability for both instruments was judged to be adequate. Conclusion. The new data derived support good and reasonable test-retest reliability for HAQ-DI and SF-36 PF in PsA.

KW - Patient-reported outcome

KW - Physical function

KW - Psoriatic arthritis

KW - Test-retest reliability

UR - http://www.scopus.com/inward/record.url?scp=85112675504&partnerID=8YFLogxK

U2 - 10.3899/jrheum.210175

DO - 10.3899/jrheum.210175

M3 - Article

C2 - 33858982

SN - 0315-162X

VL - 48

SP - 1547

EP - 1551

JO - The Journal of Rheumatology

JF - The Journal of Rheumatology

IS - 10

ER -

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this